Clinical effectiveness of primary prevention implantable cardioverter-defibrillators : results of the EU-CERT-ICD controlled multicentre cohort study
Zabel, Markus; Willems, Rik; Lubinski, Andrzej; Bauer, Axel; Brugada, Josep; Conen, David; Flevari, Panagiota; Hasenfuß, Gerd; Svetlosak, Martin; Huikuri, Heikki V.; Malik, Marek; Pavlović, Nikola; Schmidt, Georg; Sritharan, Rajevaa; Schlögl, Simon; Szavits-Nossan, Janko; Traykov, Vassil; Tuinenburg, Anton E.; Willich, Stefan N.; Harden, Markus; Friede, Tim; Svendsen, Jesper Hastrup; Sticherling, Christian; Merkely, Béla; EU-CERT-ICD Study Investigators (2020-05-06)
Markus Zabel, Rik Willems, Andrzej Lubinski, Axel Bauer, Josep Brugada, David Conen, Panagiota Flevari, Gerd Hasenfuß, Martin Svetlosak, Heikki V Huikuri, Marek Malik, Nikola Pavlović, Georg Schmidt, Rajevaa Sritharan, Simon Schlögl, Janko Szavits-Nossan, Vassil Traykov, Anton E Tuinenburg, Stefan N Willich, Markus Harden, Tim Friede, Jesper Hastrup Svendsen, Christian Sticherling, Béla Merkely, EU-CERT-ICD Study Investigators, Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study, European Heart Journal, Volume 41, Issue 36, 21 September 2020, Pages 3437–3447, https://doi.org/10.1093/eurheartj/ehaa226
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
https://creativecommons.org/licenses/by-nc/4.0/
https://urn.fi/URN:NBN:fi-fe202101252618
Tiivistelmä
Abstract
Aims: The EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter-Defibrillators (EU-CERT-ICD), a prospective investigator-initiated, controlled cohort study, was conducted in 44 centres and 15 European countries. It aimed to assess current clinical effectiveness of primary prevention ICD therapy.
Methods and results: We recruited 2327 patients with ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and guideline indications for prophylactic ICD implantation. Primary endpoint was all-cause mortality. Clinical characteristics, medications, resting, and 12-lead Holter electrocardiograms (ECGs) were documented at enrolment baseline. Baseline and follow-up (FU) data from 2247 patients were analysable, 1516 patients before first ICD implantation (ICD group) and 731 patients without ICD serving as controls. Multivariable models and propensity scoring for adjustment were used to compare the two groups for mortality. During mean FU of 2.4 ± 1.1 years, 342 deaths occurred (6.3%/years annualized mortality, 5.6%/years in the ICD group vs. 9.2%/years in controls), favouring ICD treatment [unadjusted hazard ratio (HR) 0.682, 95% confidence interval (CI) 0.537–0.865, P = 0.0016]. Multivariable mortality predictors included age, left ventricular ejection fraction (LVEF), New York Heart Association class Conclusion: In contemporary ICM/DCM patients (LVEF ≤35%, narrow QRS), primary prophylactic ICD treatment was associated with a 27% lower mortality after adjustment. There appear to be patients with less survival advantage, such as older patients or diabetics.
Kokoelmat
- Avoin saatavuus [31941]